Rice bran arabinoxylan compound and quality of life of cancer patients (RBAC - QoL): Study protocol for a randomized pilot feasibility trial PEER REVIEWED

  • Soo Liang Ooi, Sok Cheon Pak, Peter S. Micalos , Emily Schupfer, Rob Zielinski, Thomas Jeffries, Garth Harris, Terry Golombick, David McKinnon
  • (edited by Chris Gutch PhD.)
  • 2023

Introduction : Rice bran arabinoxylan com pound (RBAC) is a nutraceutical for enhancing a depleted immune system during and after cancer treatment. This pilot feasibility trial aims to evaluate the effects of RBAC on cancer patients' quality of life during active treatment, compared to placebo, using a validated questionnaire. Other outcome measures include changes in inflammatory and nutritional status, cytokine pro file, and gut mi - crobiota. Methods/ Design : The study will recruit 50 participants from a regional cancer center in Australia. Patients aged 18 –70, diagnosed with solid or an cancers stage II and above, and currently undergoing active systemic thera - pies, are eligible. Random allocation of participants into two groups is stratified based on metastatic status and treatment type. The dosage is either 3 g/ day of RBAC or placebo in identical packaging. The participants, study coordinator, and treating oncologists are blinded to the interventions. Data collections are at base line and at four follow - up sessions, which are six weeks apart (24 weeks). Statistical analysis will in volve a pro - tected p - value with multiple dependent values and analyzed by ANOVA with repeated measures on the occa - sion of testing and with both a full Bonferroni or Sidak corrections applied to protect against Type I errors. Any observed significance war rants further analysis with pair wise comparisons. Analysis of covariance will also be performed to assess any in fluence of the demographic data, cancer diagnosis, as well as changes in physical activity, dietary habits, and complementary medicine usage. Comparisons of gut microbiota will be based on the analysis of the fecal microbiome using 16S ribosomal ribonucleic acid amplicon sequencing. The proposed research time line is from October 2018 to May 2022. Trial registration : ANZCTR. Reg No: AC TRN12619000562178p.

We use cookies to improve your experience on our website. For more details see our cookie policy.

Like many other websites, we use cookies to provide enhanced functionality and track the usage of our websites with Google Analytics, and some of our third-party advertisers might use them to deliver adverts tailored to what they think you might be interested in.

What are cookies?

Cookies are small text files which can be sent to browser when you visit websites and saved to your device (computer or other device with Internet access, i.e. smartphone or tablet). Cookies are saved in the folder for files of your browser. Cookies usually contain the name of the website they come from and the date of origin. Upon your next visit the browser loads cookies again and sends these information back to the website which originally created cookies. Cookies we use do not harm your computer.

Using cookies

By using this website you give your consent to using cookies in compliance with your browser settings. If you visit our websites, acceptance of cookies is allowed in your browser, you do not change your browser settings and continue visiting our websites we consider it as accepting our conditions for using cookies.

Why are we using cookies?

Cookies are used to optimally create and constantly improve the quality of our services, adjust them to your interests and needs and improve their structure and contents. We do not use data obtained by using cookies to contact users by mail, e-mail or telephone.

How to change settings of cookies?

Majority of browsers have been originally set to automatically accept cookies. This settings can be changed by blocking cookies or by a notification in case cookies are to be sent to your device. Instructions for changing cookies are available in the option “Help” of every browser. If you use different devices to access websites (e.g. computer, smartphone, tablet), we recommend you to adjust every browser on each of them to your preferences regarding cookies.

Why to keep settings of cookies?

Using cookies and permitting cookies in your browser is your decision. However, in case you change settings of cookies, functionality of some of our websites can be limited and their user comfort reduced.